[Newsmp] In the second quarter, one-third of 44 pharmaceutical and bio companies, whose closing accounts are in December (excluding the financial industry), included in the pharmaceutical index recorded double-digit operating profit margins.
In particular, both pharmaceutical and biotech companies that achieved double-digit earnings margins entered the top 200 in the securities market, and half of them ranked in the top 100.
However, 11 of 44 pharmaceutical and bio companies, or a quarter of them, posted deficits.
According to the Korea Exchange, Chong Kun Dang Holdings had the highest operating profit of 48.6% among 44 companies in the pharmaceutical index and ranked 13th in the KOSPI market.
SK Bioscience ranked in the top 20 with an operating profit of more than 40% with 44.3%, while Celltrion placed 25th with 37.1% and Samsung Biologics with 34.1%, recording over 30% in operating profit.
Among traditional pharmaceutical companies as non-holding companies, Daewoong took the lead with 20.1% at 58th and Korea United Pharm ranked 67th with 18.3%.
Eight pharmaceutical and bio companies entered the top 100, including JW Life Science at 90th with 15.5% and Whanin Pharmaceutical at 98th with 14.5%.
Followed by the eight companies, Hana Pharm ranked 103rd with 14.4%, Pharmicell 128th with 12.9%, Daewoong Pharmaceutical 153rd with 11.4%, Dong Wha Pharm and Il Dong Holdings 163rd and 164th with 11.0%, Myungmoon Pharmaceutical 168th with 10.8%, and Daewon Pharmaceutical 180th with 10.1%, entering the top 200 with double-digit operating profit.
Moreover, Boryung Pharmaceutical with 8.1%, Chong Kun Dang Pharmaceutical with 7.7%, JW Pharmaceutical with 7.3%, and Samjin Pharmaceutical with 6.2% were in the top 300, while Hanmi Pharmaceutical, Samil Pharmaceutical, Bukwang Pharmaceutical, and Green Cross entered the top 350 with 5% mark, and Handok, Il-Yang Pharmaceutical, and Kwang Dong Pharmaceutical were placed in the top 400.
With an operating profit of 3% range, Reyon Pharmaceutical and PharmGen Science, Dong-A ST and Yuhan Corporation of 2% range, and HanAll Biopharma of 1% range ranked in the top 500 and Jeil Pharmaceutical in the 550th with 0.2%.
In the meantime, Gene One Life Science, Samsung Pharmaceutical, Il Dong Pharmaceutical, Ilsung Pharmaceutical, Dongsung Pharmaceutical, CKD Bio, Shin Poong Pharmaceutical, Yuyu Pharma, Aprogen Pharmaceuticals, Yungjin Pharm., and Kyongbo Pharmaceutical posted deficits.
